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1. INTRODUCTION 
Cerebrovascular disorders are most  devastating  disorders of 
mankind. They are supposed to be the third most common cause of death 
among developed nations. For India , numerous community surveys have 
shown a prevalence of 200 cases per 1,00,000 persons. It indicates that  
burden of stroke in INDIA constitutes 1.5 % of all urban hospital 
admissions and 4.5 % of all medical cases and  about 20 % of all 
neurological cases. 
Stroke is defined clinically and diagnosis is supported by 
investigations like imaging modalities. There is  a wide variation in the 
clinical presentation of stroke. This is because of the fact that our brain 
has complex anatomy and vasculature. Age is the predominant risk factor 
for stroke, because increasing age is associated with increased occurrence 
of  stroke.  
Three major types of stroke are now recognized. These are  
¾ Ischemic stroke 
¾ Hemorrhagic stroke  
¾ Lacunar stroke. 
Ischemic variety is due to atherothrombosis or brain embolism to 
cerebral vessels. 
Hemorrhagic stroke with bleeding within the nervous tissue occurs 
due to ruptured cerebral aneurysms  in the young and hypertensive 
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2.AIM OF STUDY 
 
To measure the blood glucose levels within  twenty four hours of  
the onset of stroke  in both diabetics and in non diabetics and to evaluate 
the clinical outcome of stroke in relation to admission day glycemic 
status.  
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3.REVIEW OF LITERATURE 
DEFINITION 
Stroke 
Defined as rapid onset of  focal neurologic deficit  resulting from 
diseases of the cerebral vasculature and its contents, the neurological 
signs and symptoms lasting for more than 24 hours1. 
Transient ischemic attack 
Implies complete recovery of such a deficit within 24 hours 
Reversible ischemic neurological deficit2 
Implies neurological deficit resolves within 7 days 
RISK FACTORS2 
MAJOR 
¾ Hypertension 
¾ Smoking 
¾ Diabetes mellitus 
¾ Obesity 
¾ Hyperlipidaemia 
¾ Polycythemia 
¾ High plasma fibrinogen 
¾ Cardiac lesion 
• Atrial fibrillation 
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• Mitral valve prolapse 
• Rheumatic heart disease 
• Ischemic heart disease 
• Infective endocarditis 
• Dilated cardiomyopathy 
¾ Thrombocythemia 
¾ IncreasingAge 
¾ TIA 
¾ Angina 
¾ Claudication 
¾ Hypercoagulable disorders  
MINOR 
¾ High alcohol intake( Binge drinking) 
¾ Positive family history of stroke 
¾ Oral contraceptive pills 
¾ Trauma 
DIABETES MELLITUS 
Diabetes mellitus increases the risk of cerebrovascular disease 
compared with the risk in people without diabetes. In addition, diabetes 
mellitus increases morbidity and mortality after stroke. Macro vascular 
disease and micro vascular disease are responsible for the complications 
among patients with diabetes mellitus3. The mechanisms of stroke 
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secondary to diabetes may be caused by atherosclerosis or embolism from 
cardiac source. The excess stroke risk in diabetes is not dependent on age 
and other factors like blood pressure levels. 
HYPERGLYCEMIA AND STROKE 
 Numerous literatures show evidence for a detrimental association 
between blood glucose levels and grave outcome of stroke patients. 
Hyperglycemia aggravates cerebral edema because it affects the integrity 
of blood brain barrier4. It elevates the levels of neurotoxic substance like 
glutamate4. Numerous studies throw light about the neuroprotective role 
of insulin.10 Furthermore chances for hemorrhage transformation are 
more with increased blood glucose levels. 
MECHANISM OF INJURY BY HYPERGLYCEMIA 
Hyperglycemia stimulates the production of lactic acid5, 6, 7 by the 
mechanism of anaerobiosis. This leads to the severe damage of penumbra 
as evidenced by advanced MRI techniques. Hyperglycemia also affects 
mitochondrial function and also generates free radicals.8 
PATHOPHYSIOLOGY OF STROKE 
Cerebral infarction is usually attributed to partial or total occlusion 
of its regional microvasculature by thromboembolism. Cerebral atheroma 
is the most common underlying intimal vascular pathology whereas 
thrombosis with arteritis (tuberculosis, syphilis, rheumatic) is not an 
uncommon cause for stroke in the young in India. Studies indicate that 
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CAUSES OF STROKE 
MAJOR CAUSES 
¾ Obesity 
¾ Hypertension 
¾ Smoking 
¾ Diabetes mellitus 
¾ Atrial fibrillation 
¾ Heart disease 
¾ Dyslipidemia 
¾ Hyperfibrinogenaemia 
¾ Alcohol 
¾ Coagulopathies 
¾ Contraceptive pill 
HYPERCOAGULABLE DISORDERS 
¾ Polycythemia 
¾ Sickle cell disease 
¾ Thrombotic thrombocytopenic purpura 
¾ Paroxysmal nocturnal  hemoglobinuria 
¾ Lupus anticoagulant 
¾ Protein C deficiency 
¾ Protein S deficiency 
¾ Antithrombin III deficiency 
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¾ Homocysteinaemia 
¾ Leukemia 
CARDIAC CAUSES 
¾ Rheumatic valve disease 
¾ Atrial fibrillation 
¾ Prosthetic heart valves 
¾ Myocardial infarction/ventricular aneurysm 
¾ Atrial aneurysm 
¾ Mitral valve prolapse 
¾ Calcific aortic valve 
¾ Cardiomyopathy 
¾ Bacterial endocarditis 
¾ Patent foramen ovale 
¾ Mitral annular calcification 
¾ Cardiac operation 
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RARE CAUSES 
¾ Marfan syndrome  
¾ Marantic endocarditis 
¾ Meningovascular syphilis 
¾ Moyamoya disease 
¾ Mitochondrial cytopathy[ MELAS] 
¾ Arterial dissection 
¾ Ehlers-Danlos syndrome 
¾ Fibromuscular dysplasia 
¾ Pseudoxanthoma elasticum 
¾ Fabry’s disease 
¾ Scleroderma 
¾ Collagen vascular disease 
¾ Hanging/strangulation 
¾ Drug abuse 
¾ Cervical irradiation 
CLINICAL CLASSIFICATION OF STROKE3 
1.COMPLETED STROKE 
Rapid in onset with persistent neurological deficit which does not 
progress beyond 96 hours. 
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2.EVOLVING STROKE 
Gradual step wise onset of neurological deficit 
3.TRANSIENT ISCHEMIC ATTACK 
4.REVERSIBLE ISCHAEMIC NEUROLOGICAL DEFICIT 
5.STUTTERING HEMIPLEGIA 
Internal carotid lesions show repeated episodes of TIA followed by 
fully evolved stroke. 
YOUNG STROKE2 
Stroke occurring in persons below 40 years of age. 
CLINICAL FEATURES 
GENERAL EXAMINATION 
General examination may show the following. 
¾ Obesity 
¾ Feeble or absent peripheral arterial pulsations 
¾ Vascular bruits 
¾ Unequal or raised blood pressure 
¾ Postural hypotension 
¾ Retinopathy  
The Stroke   may announce itself abruptly as a major catastrophic 
event due to accomplished infarction or completed stroke.  When the 
stroke evolves in a step – wise manner, appearing in each limb in 
succession, it is called ‘thrombosis in evolution’. This stuttering or 
12 
 
intermittent progression is classical of atherothrombosis. The other 
clinical manifestation depends on the site of arterial occlusion. The 
specific neurovascular syndromes are described below. 
INTERNAL CAROTID SYNDROME2 
The cervical portion of the internal carotid artery near the carotid 
sinus is a common site for  Athero-stenosis. Most of the 60 % of all 
thrombotic lesions are located here. These lesions can be asymptomatic 
due to the presence of extensive collateral circulation. A pathognomonic 
feature of carotid artery syndrome is the occurrence of ipsilateral 
monocular blindness, accompanied by contralateral hemiplegia or sensory 
deficit. But this classical feature is seen in 15 % to 20 % of the patients.  
Clinical features of acute carotid artery occlusion are almost 
indistinguishable from those of middle cerebral syndrome. Clinical 
features are as follows. 
¾ Ipsilateral monocular transient blindness. 
¾ Feeble internal carotid pulsations 
¾ Feeble superficial temporal artery pulsation 
¾ Dilated pupil 
¾ Fundus- poorly pulsating vessels on the side of lesion. 
¾ Ocular or cervical bruit on ipsilateral side. 
¾ Investigations of choice are carotid duplex, Doppler sonography& 
Angiography, which show extent and degree of stenosis. 
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Asymptomatic cervical bruit2,3 
¾ Asymptomatic patients around the age of 55- 80 years may have 
carotid bruit in the neck in about 5 % of cases. 
¾ It is difficult to correlate the presence of bruit to subsequent TIA or 
stroke in that territory unless it is haemodynamically significant. 
¾ Antiplatelet therapy is preferred in these patients. 
¾ The role of prophylactic endarterectomy in preventing future stroke 
has not been established by clinical trials. 
MIDDLE CEREBRAL SYNDROME 
AREAS SUPPLIED BY MCA 
Cortical branches 
Supply lateral surface of the cerebral hemisphere. 
Penetrating branches 
Supply  putamen , globus pallidus,  genu  and posterior limb of the 
internal capsule. Lenticulo –striate branches is other name for penetrating 
vessels. 
Clinical picture is as follows, 
¾ Contralateral hemiplegia 
¾ Hemianaesthesia 
¾ Homonymous hemianopia 
¾ Aphasia (if  dominant hemisphere involved ) 
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BROCAS APHASIA1,2 
¾ Brocas area is the motor speech area (area44 ) .  It is located in the 
posterior most portion of inferior third frontal convolution of the 
dominant hemisphere. 
¾ It is important for fluency, rhythm of speech and for the 
maintenance of grammar and syntax. 
¾ This aphasia is due to the blockage of superior division, features 
are contralateral hemiparesis with sensory deficit and expressive 
aphasia.(motor aphasia).   
¾ The patient will be non-fluent, agrammatic, dysprosodic and may 
be mute. 
WERNICKES APHASIA2,3 
¾ Wernicke area is situated in dominant tempero – parietal – 
occipital region at the posterior part of  area 22.  
¾ Its role is comprehension of the received speech  and in the 
selection of words to express ideas. 
¾ Patients present with features like fluent speech, incomprehension, 
no repetition, alexia, agraphia , paraphasia .   
¾ Site of lesion is the inferior division of  MCA. 
¾ Speech  contains paraphasia , neologism  and jargons. 
¾ When lesion in temporal region, there is disturbance in words 
heard. 
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¾ When lesion is in parieto-occipitalregion , there is disturbance of 
words seen. 
CONDUCTION APHASIA 
¾ Paraphasia , difficulty in repetition  and in reading aloud  and with 
normal  comprehension  are the common features. 
¾ Site of lesion is posterior branch of MCA. 
¾ Associated features include contralateral hemihypesthesia,  
homonymous hemianopia  and optokinetic nystagmus. 
¾ Patient has impaired repetition. ( inability of the patient to repeat  
words spoken by the examiner ) 
GLOBAL APHASIA1 
¾ There are marked elements of   both anterior ( broca ) and posterior 
( Wernicke s aphasia ). 
¾ Minimal speech/nonfluent 
¾ Comprehension for spoken and written –poor 
¾ Lesion site is internal carotid and middle cerebral arteries. 
¾ Associated features include hemiplegia, hemianopia and hemi 
sensory loss. 
ANTERIOR CHOROIDAL SYNDROME3 
Areas supplied , 
¾ Supplies posterior limb of internal capsule, which carries the 
corticospinal and sensory fibres for the contralateral limb. 
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¾ This syndrome is characterized by dense sensory-motor hemiplegic 
syndrome. 
¾ This syndrome represents a true capsular hemiplegia ( dense 
hemiplegia , hemianaesthesia and homonymous hemianopia) 
ANTERIOR CEREBRAL SYNDROME 
Areas supplied by ACA 
¾ Cortical branches supply medial superior surface of the frontal lobe 
and the parietal lobe up to the Para central lobule. 
¾ Penetrating branches supply anterior limb of the internal capsule 
and part of the head of caudate nucleus. 
Occlusion of A1 segment is usually well tolerated due to the 
presence of extensive collateral circulation. 
An anterior cerebral artery occlusion proximal to the anterior 
communicating artery in subjects with a symmetrical circle of Willis is 
frequently asymptomatic. 
Occlusion distal to the anterior communicating artery manifests 
itself by a sensorimotor paralysis of the opposite lower extremity with 
mild weakness of the opposite shoulder.2 
Occlusion  of unpaired anterior cerebral artery ( supplying both the 
hemispheres) results in a cortical type of paraplegia, sphincter 
incontinence  and a mental state in which the patient is alert but mute. 
This state is called as akinetic mutism. 
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¾ Aphasia and hemianopia are never seen. 
¾ Occlusion of the Heubner’s artery is frequently associated with 
ataxic tremors of the contralateral limbs called as frontal ataxia.  
Apraxia,idiomotor dyspraxia of the limbs and gait are also present. 
¾ Atretic anterior communicating artery presents with stroke. 
¾ Reason for occlusion of the anterior cerebral artery  is usually 
embolism , source of which could be cardiac or from major 
arteries. 
¾ There is evidence of literature highlighting occlusion caused by 
surgical prodedure like aneurysmal clip. 
SIGNS AND SYMPTOMS STRUCTURES INVOLVED 
Paralysis of opposite face, arm and leg Somatic motor area 
Sensory impairment of same area Somatic sensory area 
Motor speech disorder Broca’s area  
Homonymous hemianopia Optic radiation deep to second 
temporal convolution. 
Central aphasia, word deafness , 
anomia,alexia, agraphia 
Central language area 
Paralysis of conjugate gaze to the 
opposite side. 
Frontal contraversive field. 
Pure motor hemiplegia Superior half of the internal  capsule. 
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OCCLUSION OF A2 SEGMENT2 
SIGNS AND SYMPTOMS STRUCTURES INVOLVED 
Paralysis of opposite foot and leg. Motor leg area 
Paresis of opposie arm Involvement of arm area of cortex. 
Cortical sensory loss over toes , foot and leg. Sensory area for  foot and leg. 
Urinary incontinence Superior frontal gyrus 
Contralateral grasp and sucking reflexes Medial surface of the posterior frontal 
lobe. 
Abulia ,motor inaction Superomedial lesion near subcallosum. 
Impairment of gait and stance Infero- medial frontal striatal region. 
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POSTERIOR CEREBRAL ARTERY2,3 
PCA occlusion can be either in the central territory or in the 
peripheral territory. 
PERIPHERAL TERRITORY (cortical branches ) 
SIGNS AND SYMPTOMS STRUCTURE INVOLVED 
Homonymous hemianopia with 
macular sparing 
Calcarine cortex 
B/L homonymous hemianopia , 
cortical blindness 
Bilateral occipital lobe 
Dyslexia without agraphia Dominant calcarine lesion 
Memory defect Inferomedial position of temporal 
lobe bilaterally 
Topographic disorientation Nondominant calcarine gyrus 
Simultagnosia Dominant visual cortex 
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PCA CENTRAL TERRITORY2 
SIGNS AND SYMPTOMS STRUCTURES INVOLVED 
Thalamic syndrome-all modalities 
of sensory loss, spontaneous pain 
Ventral postero lateral nucleus of 
thalamus 
Thalamo perforate syndrome-
crossed cerebellar ataxia with 
ipsilateral 3rd nerve palsy 
Dentatothalamic tract 
Ipsilateral 3RD nerve palsy and 
contralateral hemiplegia 
Cerebral peduncle and 3rd nerve 
Paralysis of vertical eye movement, 
skew deviation 
Supranuclear fibres to 3rd nerve , 
high midbrain tegmentum 
 
VERTEBRAL ARTERY SYNDROMES 
They are the chief arteries of medulla, supplying the following structures 
¾ Lower three-fourths of the pyramid 
¾ Medial lemniscus 
¾ Lateral medullary region 
¾ Inferior cerebellar peduncle 
LATERAL MEDULLARY SYNDROME1,2 
Due to occlusion of any of the following vessels. 
¾ Vertebral artery 
¾ Posterior inferior cerebellar artery 
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¾ Superior/inferior/ middle lateral medullary arteries. 
CLINICAL FEATURES 
Clinical features indicate lateral medullary infarction. 
ON THE SIDE OF LESION 
1. Pain, numbness and impaired sensation over half the face  
(descending tract and nucleus of fifth nerve). 
2. Ataxia of limbs , falling to the side of lesion ( cerebellum , 
olivocerebellar fibres, restiform body )1,2 
3. Vertigo , nausea , vomiting , nystagmus , diplopia , oscillopsia 
(vestibular nuclei involvement) 
4. Horner’s syndrome (miosis, ptosis, anhydrosis  due to involvement 
of the descending sympathetic tract ) 
5. Loss of taste (nucleus and tractus solitarius) 
6. Dysphagia, hoarseness, vocal cord paralysis , diminished gag reflex 
(ninth and tenth nerves) 
7. Hiccup 
8. Numbness of ipsilateral arm , trunk or leg (cuneate and gracile 
nuclei ) 
ON THE OPPOSITE SIDE1,2 
Impaired pain and thermal sense over half of the body, sometimes 
face (due to involvement of spinothalamic tract). 
   
22 
 
MEDIAL MEDULLARY SYNDROME 
This syndrome is due to occlusion of vertebral artery or branch of 
vertebral or lower basilar artery. 
CLINICAL FEATURES 
ON THE SIDE OF LESION 
Paralysis and atrophy of half of the tongue.(twelfth nerve). 
ON THE OPPOSIDE SIDE 
¾ Paralysis of arm and leg sparing face (pyramidal tract) 
¾ Impaired tactile and proprioceptive  sense over half the body                       
(medial lemniscus) 
A combination of medial and lateral medullary syndrome can occur 
as a result of occlusion of vertebral artery. 
BASILAR ARTERY SYNDROMES3 
Complete basilar artery syndrome:       
Features are bilateral long tract signs with variable cerebellar, 
cranial nerve and other segmental abnormalities of the brain stem. 
Occlusion of branches may result in various combinations of symptoms 
and signs. Features include somnolence,visual  hallucinations ,  memory  
deficit  ,disorders of eye movements , skew deviation of the eyes,  
confusional state and visual defects. 
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LOCKED IN SYNDROME3 
¾ Quadriplegia with bilateral conjugate , lateral gaze palsy and mute 
state with fully preserved consciousness. 
¾ Due to infarction of the basis pontis sparing the tegmentum  from a 
mid basilar occlusion. 
OCCLUSION OF THE SUPERIOR CEREBELLAR ARTERY 
¾ Ipsilateral cerebellar ataxia 
¾ Loss of pain and temperature over the opposite side of the body 
due to the involvement of the spinothalamic tract. 
¾ Partial deafness 
¾ Ipsilateral Horner’s Syndrome 
¾ Palatal myoclonus 
¾ Nausea , vomiting , slurred speech, static tremor of the ipsilateral 
upper extremity 
OCCLUSION OF THE ANTERIOR INFERIOR CEREBELLAR 
ARTERY 
Features are vertigo , nausea  , vomiting , nystagmus , tinnitus ,  
deafness, facial weakness, ipsilateral cerebellar ataxia, ipsilateral 
Horner’s syndrome , paresis of lateral conjugate gaze , contralateral loss 
of pain and temperature with or without hemiplegia. 
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AORTIC ARCH SYNDROME 
It is characterized by diminution or absence of the arterial 
pulsations in the vessels of the arms and neck. 
Etiology 
¾ Atheromatosis 
¾ Congenital anomalies 
¾ Trauma with or without aneurysm 
¾ Chronic dissecting aneurysm 
¾ Mediastinal tumours 
¾ Thrombophilia 
¾ Syphilitic aortitis 
TRANSIENT ISCHEMIC ATTACKS2,3(TIA syndrome) 
Approximately 80% of ischemic strokes occur in the carotid (or 
anterior) circulation, and 20% occur in the vertebrobasilar (or posterior) 
circulation.  
During a follow up of nearly five years, 30 % of TIA patients   
develop a full fledged stroke. 
Many theories are proposed for TIA ,  out of which  embolic 
hypothesis and hemodynamic crisis are gaining support. 
Repetitive ( 5- 10 attacks / day ) short lived ( 15 min) typical spells 
of arm and hand weakness suggest proximal  arterial narrowing  with 
poor collateral circulation. 
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On the other hand, a single spell of speech difficulty with or 
without arm involvement  lasting for about 12 hours  suggests embolic 
ischemic attack with some degree of infarction. 
The specific type of TIA points to the particular artery involved 
TYPES OF TIA2,3 
1.LOW FLOW TIA 
Brief, recurrent and stereotyped. Due to atherosclerotic lesion at 
internal  carotid artery or MCA stem or junction of vertebral and basilar 
artery. 
2.EMBOLIC TIA 
Discrete , usually single and more prolonged. If lasting for more 
than 24 hours, it indicates infarction has already occurred. 
3.LACUNAR TIA 
Occlusion of small vessels due to lipohyalinosis. 
4. CRESCENDO TIA 
TIA occurring in increased number and frequency and having a 
high likelihood of evolving into stroke. 
BLOOD SUPPLY OF SPECIFIC BRAIN AREAS2 
THALAMUS 
Supplied by posterior communicating artery , basilar and posterior 
cerebral artery. 
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MIDBRAIN 
Supplied by posterior cerebral, superior cerebellar and basilar 
artery. 
MEDULLA OBLONGATA 
Supplied by vertebral artery, anterior and posterior spinal artery , 
posterior inferior cerebellar and basilar artery. 
CEREBELLUM 
Supplied by  superior cerebellar , anterior inferior cerebellar  and 
posterior inferior cerebellar artery. 
CORPUS STRIATUM 
Supplied  by medial and lateral central branches of MCA 
BLOOD SUPPLY OF INTERNAL CAPSULE 
Divided into anterior and posterior limb. 
ANTERIOR LIMB 
¾ Upper Half- MCA 
¾ Lower Half-ACA 
POSTERIOR LIMB 
¾ Upper Half-MCA 
¾ Lower Half-Anterior choroidal and posterior communicating 
artery. 
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EYE POSITION IN HEMIPLEGIA3 
1. Hemisphere lesion-eye deviated towards side of lesion. 
2. Pontine lesion-eyes deviated to paralysed side. 
3. Putamen lesion-loss of conjugate lateral gaze. 
4. Thalamic lesion-loss of upward gaze, skew deviation, unequal 
pupil, lateral gaze palsy. 
LOCALISATION OF THE SITE OF LESION3 
NO 
 
SITE 
OF  LESION 
LOCALISING CLINICAL FEATURES 
1. Cortex Aphasia ,bladder involvement ,cortical sensory 
loss, denial, epilepsy 
Flaccid mono or hemiplegia 
2. Internal 
capsule 
Hemiplegia , hemianaesthesia, hemianopia, marked 
spasticity 
3. Thalamus Fleeting hemiparesis in the side opposite to lesion. 
Impairment of Superficial and loss of deep 
sensation in the opposite side. Spontaneous pains 
and hyperpathia 
4. Midbrain Weber’s syndrome-3rd nerve palsy and contralateral 
hemiplegia 
Benedikt’s syndrome-3rd nerve palsy, contralateral 
cerebellar or rubral tremor and contralateral 
hemiplegia. 
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5. Pons Millard-Gubler syndrome-Ipsilateral facial 
and gaze palsy, contralateral hemiplegia. 
Foville’s syndrome-Ipsilateral6th ,7th nerve palsy 
and contralateral hemiplegia. 
6. Medulla  Medial medullary syndrome 
Lateral medullary syndrome 
7. Spinal cord Same side hemiplegia 
 
STROKE 
CLINICAL 
FEATURES 
EMBOLISM THROMBOSIS HAEMORRHAGE 
Age  Younger Middle or old Middle or old 
Mode of onset Acute Insidious Acute 
Time of onset Often during day Often during sleep During waking hours 
Convulsions Present Absent Present 
Hypertension Absent Absent Present 
Cardiac lesion Present   Absent Absent 
Recovery Rapid recovery Gradual delayed 
 
DIFFERENTIAL DIAGNOSIS 
1. Hypoglycemia 
2. Post-epileptic hemiplegia 
3. Subdural hematoma 
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4. Head injury 
5. Hysteria 
6. Posterior fossa tumours 
DIAGNOSTIC EVALUATION OF STROKE11,12 
IMAGING: 
CT SCAN 
¾ Computerised cranial tomography is the non-invasive investigation 
of choice to distinguish an ischemic infarction and cerebral 
hematoma from other conditions simulating stroke like subdural 
hematoma and tumour. 
¾ It clearly shows the extent and location  of supratentorial cerebral  
infarction 
¾ It can detect small lacunar infarct of up to 0.5 cm. 
¾ CT scan clearly highlights surrounding edema and haemorrhagic 
infarction. 
DRAWBACKS OF CT 
¾ Does not differentiate early ischemic lesion from normal tissue, 
meaning CT taken within 1 to 3 hours of stroke onset. 
¾ Brainstem lacunae are difficult to detect by conventional CT scan. 
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MRI BRAIN3 
¾ Magnetic Resonance Imaging { T2 weighted, diffusion and 
perfusion weighted studies ,MRA} of brain will define arterial  and 
cerebral lesions even in hyper acute stage, which are not visualized 
on routine CT. 
¾ MRI/MRA helps in taking therapeutic decisions like thrombolytic 
therapy. 
¾ T1- haemorrhage appears hyperintense. 
¾ T2-haemorrhage has mixed intensity. 
OTHER INVESTIGATIONS 
¾ Complete haemogram 
¾ Routine baseline investigations, ECG, x-ray chest 
CAROTID DOPPLER 
Special investigations 
¾ C-reactive protein 
¾ Lupus anticoagulant 
¾ Homocystein level 
¾ VDRL 
¾ HIV 
¾ Anti-nuclear antibodies 
¾ Anti-DS DNA 
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CT IN ISCHAEMIC STROKE13 
STAGES OF INFARCT CT FINDINGS 
< 12 hours Normal in 50 %  
Hyperdense artery  
Obscuration of  lentiform nuclei 
12 – 24 hours Insular ribbon sign 
Sulcal effacement 
1-7 days Mass effect , wedge shaped low density area  
1-8 weeks Contrast enhancement 
Mass effect resolves 
Months to years Encephalomalacic change 
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MRI IN CEREBRAL INFARCTION13 
STAGES OF 
INFARCTION 
MRI FINDINGS 
Immediate Alteration of perfusion/diffusion coefficient 
<12 hours Sulcal effacement 
12-24 hours Leptomeningeal enhancement 
Mass effect 
1 to 3 days Early parenchymal contrast enhancement 
4 to 7 days Parenchymal enhancement,Haemorrhage (25%) 
1 to 8 weeks Mass effect resolves, haemorrhage signal evolves 
Months to years Encephalomalacic  changes 
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HYPERGLYCEMIA AND STROKE OUTCOME 
Mortality and morbidity from stroke is increased in patients 
admitted with hyperglycaemia. There are multiple mechanism by which 
hyperglycaemia influences stroke outcome. 
Detrimental effects of hyperglycemia have been studied in multiple 
human and  animal studies. Hyperglycemia occurs in stroke either as a  
manifestation  of preexisting undiagnosed diabetes mellitus  or  as a  
result  of  sympathetic  response of the body  due to the  release  of 
cortisol  and  noradrenaline. 
1. Vascular occlusion causes hypoxic atmosphere in the neurons. As a 
result, glucose is converted to lactic acid by anaerobic metabolism. 
Glucose is delivered more to the ischemic zone due to damage of 
blood brain barrier. Acidosis causes damage to neurons ,neuroglial 
tissue and vascular areas.14,15,16 
2. Hyperglycemia stimulates the release of excitatory 
neurotransmitters like glutamate and aspartate. These 
neurotransmitters are neurotoxic in nature. They cause hyper 
stimulation of postsynaptic nerve terminals, resulting ultimately in 
neuronal death.17,19 
3. Numerous studies have clearly indicated that hyperglycemia 
increases calcium levels in the neurons, causing cell injury and 
death.20,21 We are already aware of the fact that nimodipine , a 
calcium channel blocker has definite role in reducing cerebral 
acidosis. 
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4. Hyperglycemia stimulates the formation of advanced glycation end 
products. These products interfere with the function of various 
enzymes. Also  these products result in toxic damage to the 
endothelial cells. Thus vascular injury is aggravated.22,23,24 
5. A negative impact on the stroke outcome by hyperglycemia  is 
explained by the fact that poor reperfusion occurs due to the 
vascular injury.25 
6. Another disastrous effect is the loss of vascular tone  due to the 
oxidation of the nitric oxide dependent mechanisms.26,27,28 
7. Martini and Kent  state that even when a blocked vessel  is 
recanalized promptly, effective reperfusion  of  ischemic   brain  
tissue is not obtained.29,30 
8. Function of mitochondria is severely impaired in the zone of 
ischemic penumbra. As a result , size of the infarct 
progresses.31,32,33 
9. Another crucial factor is increased lipolysis due to insulin deficient 
state, resulting in  free fatty acid  production.    As a result , 
ischemic brain tissue is further damaged.34,35,36 
Numerous studies have shown that admission day glucose level 
directly correlates with the occurrence of cerebral edema and its known 
deadly complications causing clinical deterioration of the patient. Blood 
glucose level is one of the determinant of infarct progression. 
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TREATMENT OF ISCHEMIC STROKE2,3,18 
GOAL OF THERAPY 
1. Avoid the development of cerebral infarction. 
2. If already developed, then the goal is to reduce its progression and 
recurrence. 
MANAGEMENT OUTLINE 
1. Medical management 
2. Antiplatelet drugs 
3. Anticoagulants 
4. Thrombolytic therapy 
• Intravenous 
• Intra-arterial 
5. Neuroprotective agents 
6. Surgical management 
Treatment is divided into three phases. 
PHASE 1 
Saving life and speedy recovery 
PHASE 2 
Rehabilitation to achieve adaptation to gainful employment. 
PHASE 3 
Prevention of recurrence of stroke. 
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PHASE 1 
GENERAL MEASURES 
¾ Maintenance of vital signs 
¾ Airway patency 
¾ Fluid and electrolyte balance 
¾ Prevention of complications like pulmonary aspiration, bedsores. 
BLOOD PRESSURE CONTROL3 
Due to loss of cerebral auto regulation, perfusion in the ischemic 
zone is solely dependent on mean arterial BP. In the presence of severe 
hypertension (BP-220/120mmhg), intravenous agents like labetalol or 
enalapril which reduce the BP smoothly are preferred. Calcium channel 
blockers are avoided because they produce marked fall in BP. 
FLUID/ELECTROLYTE AND BLOOD GLUCOSE 
Hyperglycemia or hypoglycaemia should be treated appropriately. 
Hyperglycemia adversely influences stroke outcome. Hence according to 
American Diabetes Association, strict glycemic control with insulin 
therapy is preferred. 
IV 5% dextrose is best avoided in early stages of infarction with 
edema. 
Judicious restriction of fluid intake is advocated in first 48 hours. 
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REDUCTION OF INTRACRANIAL PRESSURE AND CEREBRAL 
EDEMA1,2 
¾ Head elevation by 30 degree. 
¾ If associated with increasing drowsiness, intubation and 
hyperventilation to maintain pCO2 around 25-30 mmhg would be 
helpful. 
¾ Hyperosmolar solution like intravenous mannitol will reduce 
vasogenic brain edema. Its contraindications are renal failure and 
cardiac failure.  
¾ IV 10% glycerol has role in reducing edema in patients with 
incipient left ventricular failure. 
¾ Restriction of fluids and furosemide induced diuresis is also 
effective in reducing edema. 
¾ High dose of corticosteroids reduces cerebral edema but its role in 
the management of vasogenic edema is doubtful. 
¾ Careful reduction of BP in situations of hypertensive crisis using 
parenteral antihypertensive is greatly helpful. 
HAEMODILUTION THERAPY 
Haematocrit is the chief determinant of whole blood viscosity. 
Lowering of haematocrit to 30% - 33 % improves cerebral blood 
flow and oxygenation of infracted tissues. But recent trials showed no 
consistent benefit of haemodilution therapy. 
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SPECIFIC THERAPY 
ANTIPLATELET DRUGS4 
¾ ASPIRIN 
¾ TICLOPIDINE 
¾ CLOPIDOGREL 
¾ GlycoproteinIIb/III a inhibitors 
Abciximab 0.25mg/kg IV bolus 
Aspirin prevents platelet aggregation by blocking production of 
platelet derived thromboxane –A2. Its widely used in primary and 
secondary prevention of stroke. 
Ticlopidine inhibits ADP-induced transformation of                    
glycoprotein IIb/IIIa receptors on platelet membrane. Patients with raised 
creatinine levels benefit more with ticlopidine 250 mg bid. MATCH 
study revealed no real benefit in outcome of vascular end points with 
combination therapy of aspirin and clopidogrel. 
ANTICOAGULANTS 
INDICATIONS OF HEPARIN IN STROKE 
¾ Cardio-embolic stroke 
¾ Dissection of carotid and vertebral artery 
¾ Hypercoagulable states like protein C deficiency / protein S 
deficiency. 
¾ Cerebral venous thrombosis 
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¾ Recurrent TIA s 
¾ Thrombosis in evolution 
Dosage is 3000 to 5000 units given every 6 - 8thhourly.APTT is 
kept up to two times the control. 
Among oral anti-coagulants, coumarin sodium 2-5 mg/day is 
generally well tolerated. 
THROMBOLYTIC THERAPY 
INDICATIONS 
¾ When stroke is clinically suspected. 
¾ Symptom duration < 3 hours 
¾ Consent by patient  
¾ CT SCAN revealing no haemorrhage or significant cerebral edema. 
¾ Patient should have crossed the age of eighteen years. 
DOSE OF rtPA- 
Recombinant tissue plasminogen activator is administered as 
follows. Maximum dose is 90 mg. Total dose is 0.9 mg/kg IV.  Total dose 
is calculated as per body weight.  Dose for bolus injection is 10 % of the 
calculated dose. The remaining dose of 90 % is given  intravenously as a 
continuous infusion for a estimated time of about one hour. 
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INTRA-ARTERIAL THROMBOLYTIC THERAPY 
Latest advances using microcatheter techniques enables to inject 
thrombolytic agent directly over the clot surface, thereby giving more 
effective recanalization. 
NEUROPROTECTIVE AGENTS 
Clinical trials with multiple agents like calcium channel blocker 
nimodipine have not shown clear benefits in several vascular endpoints. 
Results of several trials awaited. 
HOMOCYSTEINE3 
Elevated levels of homocysteine affects endothelial cell function 
and also cause oxidative stress, ultimately leading to thrombosis. 
Treatment with multivitamins like B6, B12 and folic acid helps in 
reducing homocysteine levels and thus reducing vascular complications. 
STATINS 
SPARCL study indicates that statins reduce the recurrence of 
cerebrovascular accident and the benefit obtained with statin is 
independent  of its  cholesterol lowering action. 
SPARCL study-stroke prevention by aggressive reduction in 
cholesterol 
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SURGICAL MANAGEMENT- 
Carotid artery endarterectomy has shown clear benefits in patients 
admitted with tight cervical stenosis defined as 70% to 99 %. In mild 
stenosis , the role of endarterectomy is controversial. 
STENTING AND ANGIOPLASTY2 
Stenting is associated with less frequent complications like 
hematoma in neck. So it is an effective alternative for patients not 
feasible for endarterectomy. Stenting along with embolic protection 
devices are accepted as alternative treatment. 
STEM CELL THERAPY 
Ethical issues prevent experimental trials in humans with stem cell 
therapy in ischemic stroke. Animal experiments need to be explored.  
Reliable reports are not available. 
PHASE 2 
NEUROREHABILITATION 
Active physiotherapeutic measures should be commenced as soon 
as the patient shows signs of recovery. This is necessary to prevent the 
occurrence of joint contracture and also to promote recovery of strength 
and coordination. 
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PHASE 3 
STROKE PREVENTION 
Chances of recurrent stroke are high during the first few weeks and 
nearly 10% of cases occur during the first year. Prevention strategies are 
¾ Control of smoking  
¾ Stop  smoking/tobacco use 
¾ Antiplatelet agents. 
¾ Anticoagulants 
¾ Statins 
¾ Glycemic control 
¾ Correction of modifiable risk factors 
¾ Regular physical exercise 
¾ Maintenance of ideal body weight. 
INTRACEREBRAL HAEMORRHAGE 
It is the deadliest, most disabling and least treatable form of stroke. 
Following a haemorrhage, 35% to 52 % are dead within a month and less 
than 20% were living independently after 6 months. It constitutes 15% of 
all stroke in the west and 20% to 30% in western population. There is 
increasing literature revealing higher incidence of haemorrhagic stroke in 
north-eastern regions. 
Most significant risk factors for haemorrhagic stroke are chronic 
uncontrolled hypertension and advancing age. 
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Haemorrhagic strokes occur in increased frequency in patients 
admitted with hyperglycemia irrespective of whether the patient is known 
diabetic or newly diagnosed diabetic or stress induced hyperglycemia. 
CAUSES OF INTRACEREBRAL HAEMORRHAGE4 
ABNORMAL BLOOD VESSELS 
¾ Vascular malformations 
¾ Arteriovenous malformations 
¾ Saccular aneurysm 
¾ Cavernous angioma 
¾ Septic and mycotic aneurysm 
¾ Lipohyalinosis 
¾ Microaneurysm 
¾ Amyloid angiopathy 
¾ Cerebral tumour 
¾ Cerebral venous thrombosis 
¾ Vasculitis 
¾ Moyamoya syndrome 
¾ Haemorrhagic transformation 
SYSTEMIC BLEEDING TENDENCY 
¾ Haemophilia 
¾ Leukaemia 
¾ Thrombocytopenia 
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¾ Anticoagulants 
¾ Antiplatelet agents 
¾ Thrombolytic agents 
ILLICIT DRUGS 
¾ Amphetamines 
¾ Cocaine 
HYPERPERFUSION SYNDROME 
TRAUMA 
SITES 
Most common sites of hypertensive haemorrhage are deep grey 
matter 
¾ Putamen 
¾ Globuspallidus     above three constitute 65% 
¾ thalamus 
¾ Subcortical white matter-10 to 20 % 
¾ Pons – 10 to 15 % 
¾ Cerebellum- 8 to 10 % 
CLINICAL FEATURES 
¾ Signs and symptoms accompanying ICH reflect the location of 
haemorrhage. 
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¾ Lobar haemorrhages frequently produce contralateral weakness or 
sensory loss, language disturbance, hemianopia and parietal lobe 
signs. 
¾ Majority of ICH cause complete stroke. 
¾ Cerebellar haemorrhage are particularly important to identify 
clinically as they require surgical intervention which can be 
lifesaving. 
INVESTIGATIONS 
Plain CT scan of the brain is the mainstay of diagnosis of ICH. 
Blood appears hyper dense on noncontrast enhanced CT scans. 
MRI Scan is also very sensitive for ICH.  Following haemorrhage, 
a series of events occurs that can be detected using MRI. It is particularly 
useful to distinguish between previous cerebral infarction and 
haemorrhage at a time when the appearance on CT are identical. 
TREATMENT 
Control of blood pressure 
¾ Head of bed elevation 
¾ Osmotic therapy 
¾ Hyperventilation 
¾ Maintenance of euvolemia 
¾ Prevention of seizures 
¾ Management of body temperature. 
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¾ Strict glycemic control in the presence of hyperglycemia 
¾ Surgery 
¾ evacuation of hematoma, VP shunt 
IMPACT OF HYPERGLYCEMIA ON HAEMORRHAGIC 
STROKE 
¾ Hyperglycemia severely impairs blood brain barrier. As a result, it 
aggravates edema formation in surrounding area of haemorrhage.9 
¾ Relative insulin deficiency further causes release of free fatty 
acids, which further aggravate neuronal damage. 
¾ Multiple studies have demonstrated  association  between  elevated 
blood glucose levels and  hemorrhagic transformation  of  ischemic  
stroke.37,38 
¾ But controversial results are also obtained in few studies.  One 
such study is the Copenhagen stroke study. The result obtained was 
diabetics had lesser frequency of hemorrhagic  stroke.40 
¾ Demchuk et al stated that  elevated  blood  glucose  is  a crucial  
predictor  of   intracerebral hemorrhage   in a study conducted  
among  138 patients  with ischemic  stroke who  received  tissue 
plasminogen  activator.41 
¾ Hyperglycemia  is a  crucial determinant of  outcome  in 
supratentorial  intracranial hemorrhage. 
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4. MATERIALS AND METHODS 
Number of patients undertaken for my study are  hundred and ten 
patients. All are admitted in the Department of Medicine, Government 
Tirunelveli medical college hospital, tirunelveli. Period of study was from 
November 2011 to October 2012. Both male and female are undertaken 
for study.  Both ischemic and haemorrhagic stroke are studied. Criteria 
for selecting patients were formulated and are as follows. 
CRITERIA FOR SELECTION 
¾ Age> 40 years 
¾ Admission to our hospital within 24 hours of onset of sroke 
¾ Measurementof blood glucose levels within 24 hours of onset of 
cerebrovascular accident. 
¾ First episode of stroke  
CRITERIA FOR REJECTION 
¾ Age< 40 years 
¾ Admission after 24 hours of onset of cerebrovascular accident. 
¾ Measurement of blood glucose levels after 24 hours of symptoms 
onset. 
¾ Recurrent stroke 
¾ Intravenous glucose administration before sample collection. 
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Among the hundred and ten patients, follow up of ten patients 
could not be done. So for my study remaining hundred patients were 
selected. 
Detailed complete neurological history taken and from the 
presentation of manifestations, clinical diagnosis was made out. 
Vital signs measurement done in all patients. 
For all admitted patients, routine basic investigations done like 
complete blood count, blood glucose, renal function test,. 
Xray chest and ECG done. 
Stroke severity is assessed on each patient considering the clinical 
presentation into account and each finding is awarded specific points. 
NIH STROKE SCALE 
1a.   Level of Consciousness: 
0 =   Alert 
1 =   drowsy 
2 =   stupurous 
3 =   comatose 
1b.  LOC Questions:  
0 =    Answers both correctly. 
1 =    Answers one correctly. 
2 =     Incorrect 
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1c.   LOC Commands:   
0 = Obeys both correctly. 
1 = Obeys one correctly. 
2 = Incorrect 
2.   Best Gaze:    
0 = Normal. 
1 = partial palsy 
2= forced deviation 
3.  Visual: 
0 = No loss of vision 
1 = Partial hemianopia. 
2 = Complete hemianopia. 
3 = Bilateral hemianopia  
4.  Facial Palsy 
0 = Normal symmetric 
1 = Minor paralysis  
2 =Partial paralysis  
3 = Complete paralysis  
5. Best  Motor Arm/Leg( right/ left ): 
0 = No drift 
1 = Drift 
2 = some antigravity effect 
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3 = No antigravity effect 
4 = No movement. 
6. Limb Ataxia: = 
0 = Absent. 
1 = Present in one limb. 
2 = Present in both limbs. 
7.Sensory:  
0 = no sensory loss. 
1 = Mild-to-moderate sensory loss 
2 = total sensory loss 
8. Best Language: 
0 = No aphasia 
1 = Mild to moderate aphasia  
2 = Severe aphasia 
3 = Mute 
9.    Dysarthria: 
0 = Normal. 
1 = Mild to moderate  
2 = Severe 
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11.   Extinction and Inattention 
0 = No abnormality. 
1 = Visual/ tactile/ spatial/ personal inattention 
2 = Profound hemi-inattention. 
From the above scale, points are added for each patient, assessing 
the severity of involvement. Maximum points that can be awarded for 
each patient are thirty points.  
PLAN OF STUDY 
¾ Blood glucose is estimated within 24 hours of onset of stroke. 
¾ All the patients are classified into 4 broad groups based on the 
following three parameters. 
• Admission Day Blood glucose 
• HBA1C level 
• History of diabetes mellitus 
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 CATEGORY 
1. Blood glucose < 110 mg/dl EUGLYCEMIC 
2. History of Diabetes Mellitus KNOWN DIABETIC 
3. Blood glucose > 110mg/dl 
No History of diabetes 
HBA1C > 6.5% 
NEWLY DIAGNOSED DIABETIC 
4. Blood glucose > 110 mg/dl 
No History of diabetes 
HBA1C < 6.5 % 
STRESS HYPERGLYCEMIC 
 
HBA1C normal range is 3.8% to 6.4 %. Only for those patients, 
presenting with blood glucose levels more than 110 mg/dl and also with 
no history of diabetes mellitus , HBA1C level is measured. 
Glucose attaches to haemoglobin in an irreversible fashion 
throughout its life span. At any given point of time, a sample represents a 
collection of new-born, middle age and senescent RBCs. Hence 
glycohaemoglobin level obtained represents a glucose level that is 
reflective of the glucose environment confronting red cells over the 
previous 3 months period. 
HBA1=HBA1 (a,b,c). HBA1C is preferred because glycosylation 
is with glucose and not with other sugars. 
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HBA1C of 6% corresponds approximately to mean plasma glucose 
of 120 mg.  For every 1 % rise in HBA1C, mean blood glucose rises by 
30 mg.  Haemolyticanemia , Haemoglobinopathies and Uraemia may 
interfere with the estimation of glycated haemoglobin.  
CT brain is done in all patients. In addition to making a diagnosis  
of stroke, size of lesion can be made out. 
SIZE OF LESION 
SMALL      -        5 mm 
MEDIUM -        5-10 mm 
LARGE -        > 10 mm 
FOLLOW UP  
All the patients under study are followed up for thirty days, 
progression of disease assessed. 10 patients are dropped as routine follow 
up could not be done. Outcome of remaining 100 patients is classified 
into 4 categories. 
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OUTCOME CATEGORY 
GOOD Improvement in symptoms along with 
independency in carrying out day to day 
activities, Motor function  and  Aphasia with no 
persistent disability 
POOR Not able to carry out any form of work with 
persistent disability and dependent on others for 
day to day activity,  
Stable deficit with no evidence of recovery 
Moderate  Patients not fitting into above two categories are 
classified as moderate. 
DEATH  
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5. OBSERVATIONS AND RESULTS 
STATISTICAL TOOLS 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and 'p'  values were calculated. Kruskul 
Wallis chi-square  test was used to test the significance of difference 
between quantitative variables and Yate’s chi square test for qualitative 
variables. A 'p' value less than 0.05 is taken to denote significant 
relationship. 
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RESULTS 
PROFILE OF CASES STUDIED 
Age distribution 
Age group Cases 
No % 
40-49 years 18 18 
50-59 years 23 23 
60-69 years 39 39 
70 & above 20 20 
Total 100 100 
Range 
Mean 
SD 
40 - 88 years 
60.1 years 
10.5 years 
 
Sex distribution 
Sex 
Cases 
No % 
Male 68 68 
Female 32 32 
Total 100 100 
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RISK FACTORS 
Risk factors Male Female Total 
Hypertension 24 16 40 
Diabetes  13 11 24 
Dyslipidemia 15 14 29 
Atrial fibrillation  1 1 2 
 Coronaryartery disease 23 3 26 
 
 
 
Personal habits among males 
Personal habits among 
males(68) 
Cases 
No % 
Smoking 4 5.9 
Alcoholic 20 29.4 
Smoker/ Alcoholic 16 23.5 
Nil 28 41.2 
Total 68 100 
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CT findings 
CT findings 
Cases 
No % 
Hemorrhage 21 21 
Infarct 79 79 
Total 100 100 
 
 
Admission day blood glucose 
Admission day  
blood sugar 
Cases 
No % 
< 110 mg 31 31 
110-125 mg 7 7 
126-199 mg 49 49 
> 199 mg 13 13 
Total 100 100 
Range 
Mean 
SD 
72 - 334 
147.4 
53.5  
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NIHSS / HbAIC 
Parameter NIHSS HbAIC 
Range 6-26 6-10.4 
Mean 12.9 6.8 
SD 6.0 1.2 
 
 
 
PROGNOSIS 
Prognosis 
Group 
Hemorrhage
Group 
Infarct 
group 
Total case 
No % No % No % 
Good 3 14.3 21 26.6 24 24 
Moderate 4 19 14 17.7 18 18 
Poor 7 33.3 28 35.4 35 35 
Death 7 33.3 16 20.3 23 23 
Total 21 100 79 100 100 100 
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GLYCEMIC STATUS 
Glycemic status Total 
Euglycemia                     31 
Stress hyperglycemia                     26 
Known diabetes                      24 
Newly detected diabetes                      19 
 
 
 
GLYCEMIC STATUS AND STROKE SEVERITY 
Glycemic status NIHSS 
Euglycemia 7.1 
Stress hyperglycemia 17.2 
Known diabetes  18.3 
Newly detected diabetes  16.5 
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SIZE OF LESION IN STROKE 
Glycemic status Small Medium Large Total 
Euglycemia 19 6 6 31 
Stress hyperglycemia 2 11 13 26 
Known diabetes  1 7 16 24 
Newly detected diabetes 1 6 12 19 
X2 =41.5    p=0.001 
 
NIHSS and clinical outcome 
 
Clinical 
outcome 
NIHSS values 
Hemorrhage 
Group 
Infarct 
group 
Total  
cases 
Mean S.D. Mean S.D. Mean S.D. 
Good 7.0 - 6.9 0.5 6.9 0.4 
Moderate 12.5 2.9 10.1 2.6 10.6 2.7 
Poor 22.1 4.0 15.1 3.7 16.5 4.7 
Death 22.4 5.6 12.5 5.7 15.5 7.2 
‘p’ 0.0054 
Significant 
0.0001 
Significant 
0.0001 
Significant 
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HbAIC and clinical outcome 
Clinical 
outcome 
HbAIC values 
Hemorrhage 
Group 
Infarct 
group 
Total 
cases 
Mean S.D. Mean S.D. Mean S.D. 
Good - - 6.1 - 6.1 - 
Moderate 8.2 3.1 6.7 1.6 7.1 1.9 
Poor 6.9 1.3 6.6 0.6 6.7 0.8 
Death 7.4 2.4 6.6 0.8 6.8 1.3 
‘p’ 0.8204 
Not significant
0.3857 
Not significant 
0.4589 
Not significant 
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ADMISSION DAY GLUCOSE LEVELS AND CLINICAL 
OUTCOME 
Clinical outcome 
Admission day glucose values 
Hemorrhage 
Group 
Infarct 
group 
Total 
cases 
Mean S.D. Mean S.D. Mean S.D. 
Good 88 6.1 94.0 20.6 93.3 19.4 
Moderate 159.3 43.4 134.6 40.7 140.1 41.3 
Poor 198.7 70.5 167.6 39.8 173.8 47.9 
Death 173.9 47.2 167.6 56.1 169.5 52.5 
‘p’ 0.0403 
Significant 
0.0001 
Significant 
0.0001 
Significant 
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GLYCEMIC STATUS AND CLINICAL OUTCOME IN 
HAEMORRHAGE GROUP 
BLOOD SUGAR 
Clinical outcome in Hemorrhage group 
GOOD MODERATE POOR DEATH TOTAL
Euglycemia 3 1 - 1 5 
Stress hyperglycemia - 1 3 2 6 
Known diabetes mellitus - 1 2 2 5 
Newly detected diabetes - 1 2 2 5 
Total 3 4 7 7 21 
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GLYCEMIC STATUS AND CLINICAL OUTCOME IN INFARCT 
GROUP 
BLOOD SUGAR Clinical outcome in Infarct group 
GOOD MODERATE POOR DEATH TOTAL
Euglycemia 19 4 2 1 26 
Stress hyperglycemia 1 5 8 6 20 
Known diabetes mellitus 1 4 9 5 19 
Newly detected diabetes - 1 9 4 14 
Total 21 14 28 16 79 
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GRADE OF BLOOD SUGAR AND CLINICAL OUTCOME IN 
HAEMORRHAGE GROUP 
BLOOD SUGAR 
LEVEL 
Clinical outcome in Hemorrhage group 
GOOD MODERATE POOR DEATH TOTAL
< 110 mgs 3 1 - 1 5 
110 – 125 mgs - - - - - 
126 – 199 mgs - 3 5 4 12 
>199 mgs - - 2 2 4 
Total 3 4 7 7 21 
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GRADE OF BLOOD SUGAR AND CLINICAL OUTCOME IN 
INFARCT GROUP 
BLOOD SUGAR 
Clinical outcome in Infarct group 
GOOD MODERATE POOR DEATH TOTAL
< 110 mgs 19 4 2 1 26 
110 – 125 mgs 1 1 4 1 7 
126 – 199 mgs 1 8 16 12 37 
>199 mgs - 1 6 2 9 
Total 21 14 28 16 79 
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6. DISCUSSION 
AGE, SEXAND RISK FACTORS 
Among our study of 100 patients, majority of them belonged to 
male sex showing a male preponderance which is commonly seen in most 
studies. Majority of the patients, 39 were between the age group of 60 to 
69 years. In our study of 100 patients, 40 patients had hypertension, 24 
patients had diabetes mellitus, 29 had evidence of dyslipidemia and 2 had 
atrial fibrillation.  Nearly half of patients had smoking as a risk factor and 
one third had history of alcohol intake.  
GLYCEMIC STATUS 
In our study of 100 patients, 69 patients had elevated admission 
day blood glucose levels and 31 patients had normal blood glucose 
values. Diabetes was noticed in 24 patients and stress 
hyperglycemianoted in  26  patients. Newly diagnosed diabetic patients 
contributed to a number of 19.  In ischemic stroke, stress hyperglycemia 
contributed to one third of patients and  in haemorrhagic stroke also, 
stress hyperglycemia contributed to one third of patients. 
SEVERITY OF STROKE 
Severity of stroke was assessed with stroke scale devised by 
national institute of health. Patients with elevated admission day blood 
glucose levels had a higher score when compared to euglycemic patients 
which was statistically significant with p value of 0.001.  This clearly 
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shows that patients with elevated admission day blood glucose levels at 
the time of stroke had severe stroke. 
SIZE OF STROKE 
All patients were subjected to CT brain and size of the lesion was 
analyzed.  Results are, most of the euglycemic patients had small sized 
infarcts and hemorrhagic lesions, whereas majority of the admission day 
hyperglycemic patients had large sized lesion with edema and midline 
shift. These data are statistically significant with p value of 0.001. As 
already discussed, hyperglycemia by means of multiple mechanisms like 
altered mitochondrial function, increased free radical production, causes 
toxic injury to brain and this is responsible for large sized infarcts and 
hemorrhages observed in patients admitted with elevated admission day 
blood glucose levels. 
TYPE OF STROKE 
In our study of 100 patients, seventy nine patients had ischemic 
stroke and 21 patients had hemorrhagic stroke. Among the euglycemic 
group, predominant patients had ischemic stroke and one fourth of 
patients had hemorrhagic stroke. Among patients with stress 
hyperglycemia, twenty patients had infarct whereas 6 patients had 
hemorrhage.  On observing diabetes mellitus patients, nineteen patients 
had infarct and the remaining patients had hemorrhage. In patients with 
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newly diagnosed diabetes, five persons presented with hemorrhage and 
fourteen presented with infarct. 
OUTCOME OF STROKE 
¾ In this study of hundred acute stroke patients, euglycemic patients had 
a better outcome when compared to admission day hyperglycemic 
patients. 
¾ Patients with normal blood glucose levels had a better recovery after 
acute stroke at the end of thirty day follow up. On the contrary, 
patients with admission day hyperglycemia are associated with either 
slower recovery or poorer recovery. 
¾ Admission day blood glucose levels have a direct correlation with 
severity of stroke. Among patients with good outcome in hemorrhage 
group, the mean blood glucose level is 88 mg, likewise for infarct 
group with good outcome, mean value for glucose is 94 mg.  
¾ For patients with poor outcome, mean blood sugar value in patients 
with hemorrhagic stroke was 198mg , whereas mean value in ischemic 
patients was  167 mg.  
¾ Regarding mortality , death is associated with mean admission day 
blood glucose  level of 173 mg in the hemorrhage group and the mean 
value for infarct group is 167 mg. These data were statistically 
significant with p value of 0.0403 for hemorrhagic stroke and  p value 
for ischemic stroke is 0.0001 which is significant.  
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¾ This study of hundred acute stroke patients shows that admission day 
elevated blood glucose levels was associated with a high early 
mortality rate and  an increased risk of poor functional recovery. 
¾ 70 % of patients with euglycemia had good outcome with speedy 
recovery in both types of stroke. On the other side, only 3.8 % of 
stress hyperglycemia had good outcome.  Among 31 patients of 
euglycemia, 6.45 % of patients showed worse outcome. On the 
contrary, 42 % of patients with stress hyperglycemia showed poor 
outcome. 
¾ Among diabetes mellitus patients (both known diabetic and newly 
diagnosed diabetics) , only 2.32  % of patients had good outcome.  But 
poor outcome was seen in as many as 51.16 % of patients with 
diabetes. Mortality rate is also high evidenced by death in 30.23 % of 
patients. These data are statistically significant with p value of 0.001. 
¾  There is straight correlation between blood sugar levels and outcome 
of cerebrovascular accident. This is evidenced by the fact revealing 
that 60 % of patients with poor outcome had blood sugar values 
between 126- 199 mgs. On comparison, only 4 % of patients with 
good outcome had blood sugar value in the range of 126-199 mg%.   
97 % of patients with good outcome had blood glucose levels in the 
range of < 110 mgs.   
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¾ Our study clearly shows a positive correlation between admission day 
sugar value and the outcome of cerebrovascular accident. Higher 
admission day elevated blood glucose level has increased mortality 
and high risk of poor functional recovery. 
COMPARISON   WITH OTHER STUDIES 
¾ A study published on July 2012 by European Journal of Neurology 
stated that expansion of infarct volume is caused by admission day 
elevated blood glucose levels44. In our study, patients with 
hyperglycemia had larger infarct when compared to euglycemia.  
¾ Another study  by University of Glascow published by cardiovascular 
and medical sciences division  conducted on 2011, indicates  
hyperglycemia in the per infarct time causes grave outcome in both 
diabetes and non-diabetes patients. Our study clearly demonstrated 
poor outcome in hyperglycemia patients.                                                                          
¾ A study published by European journal of neurology,  concluded that 
elevated  glucose level after acute stroke is associated with higher 
severity than those with normal level. The mean stroke scale was 7.1 
in patients with euglycemia and was 18.3 in patients with diabetes 
mellitus45. 
¾ Regarding insulin therapy and stroke outcome, a study was conducted 
in the year 2011 by neurology clinic, Poland stated that intensive 
insulin therapy maintaining strict glycemic control improves 
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cerebrovascular accidents outcome and concluded that insulin therapy 
is safe. 
¾ In the study by clinical endocrinology journal, patients admitted with 
elevated blood glucose levels had a significant higher early mortality 
and a lower functional outcome than patients with normoglycemia46. 
Our study conducted in hundred patients signified same results. 
¾ In our study, admission day hyperglycemia was associated with higher 
mortality and slower outcome or poor outcome in patients presented 
with both hemorrhagic stroke and ischemic stroke. Now many trials 
are under way to improve the outcome of stoke with human 
recombinant insulin for patients with hyperglycemia. Few studies have 
shown insulin administration improves functional recovery and vital 
activity of stroke. Our study has clearly demonstrated the detrimental 
effect of glucose on aggravating brain damage in stroke. 
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7. CONCLUSION 
¾ The combined diabetes and stress hyperglycemic are found to have 
larger sized severe stroke and a poor functional outcome in the 
form of increased mortality.  There is a linear correlation between 
admission day hyperglycemia and stroke in its severity, size and 
outcome. 
¾ According to a study conducted at 2007 by Bangur institute of 
neurology, Calcutta medical college, admission day elevated 
glucose level was a significant predictor of mortality and poor 
functional outcome after acute stroke 47,48.  My study has concluded 
similar results. 
¾ According to the GLIAS STUDY conducted in 2009, 
hyperglycemia in the range of >155 mg% in the first 48 hours is 
associated with poor outcome in ischemic stroke49. In my study , 
blood glucose in the range of 125-199 mg in the first 24 hours of 
onset of stroke is associated with poor outcome 
¾ According to the Harrisons textbook of medicine, 18th edition,   
blood glucose should be maintained below <110 mg/dl using 
insulin infusion if necessary. 
¾ Hence restoration of normoglycemia as soon as possible should be 
encouraged .In the interim, we should fare well with adhering to 
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good general stroke management, normalization of body 
temperature, fluid balance and hemodynamics. 
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9. PROFORMA 
NAME OF THE PATIENT : 
AGE : 
SEX : 
IP NO : 
ADDRESS : 
 
OCCUPATION : 
CHIEF COMPLAINTS : 
HISTORY OF PRESENTING COMPLAINTS : 
PAST HISTORY : 
HT / DM / TIA / PT / BA / COPD / CRF / CAHD / DCM / RHD / 
AS / MVP / HEPATIC DISEASE / SEIZURES /                         
PSYCHIATRIC DISORDERS 
PERSONAL HISTORY :SMOKING, ALCOHOLISM, DIET 
GENERAL EXAMINATION : 
VITALS :BP, PULSE RATE, RESPIRATORY RATE AND PATTERN 
CLINICAL EXAMINATION : 
CENTRAL NERVOUS SYSTEM : 
CARDIOVASCULAR SYSTEM : 
 
 
RESPIRATORY SYSTEM : 
ABDOMEN EXAMINATION : 
SPINE AND CRANIUM : 
CLINICAL DIAGNOSIS : 
INVESTIGATIONS : 
¾ Blood sugar , urea , Serum creatinine 
¾ Serum electrolytes : sodium, Potassium 
¾ Blood hemoglobin , TC , DC, ESR 
¾ Urine albumin , sugar , deposits 
¾ Total cholesterol 
¾ Electrocardiogram 
¾ Chest X ray 
¾ CT scan brain 
¾ Glycosylated Hemoglobin when required 
FINAL DIAGNOSIS : 
PROGNOSIS (30 DAY FOLLOW UP) 
¾ Good / Moderate / Poor / Death 
 
 
 
ABBREVIATIONS 
HT  - Hypertension  
DM  -  Diabetes  mellitus  
CAHD -  Coronary artery heart disease    
DCM  -  Dilated cardiomyopathy   
AF   -  Atrial fibrillation 
HBA1C -  Glycosylated hemoglobin   
ACA  -  Anterior cerebral artery  
MCA  - Middle Cerebral Artery   
PCA  -  Posterior cerebral artery   
ICH  -  Intracerebral hemorrhage  
TIA   - Transient Ischemic Attack  
COPD  -  Chronic Obstructive Pulmonary Disease 
PT   - Pulmonary Tuberculosis 
BA   - Bronchial Asthma 
CRF   -  Chronic Renal Failure 
MVP   - Mitral Valve Prolapse 
RHD   - Rheumatic Heart Disease 
  
KEY TO MASTER CHART 
HT  - Hypertension  
DM  -  Diabetes  mellitus  
CAHD -  Coronary artery heart disease    
DCM  -  Dilated cardiomyopathy   
AF   -  Atrial fibrillation 
HBA1C -  Glycosylated hemoglobin   
ACA  -  Anterior cerebral artery  
MCA  - Middle Cerebral Artery   
PCA  -  Posterior cerebral artery   
ICH  -  Intracerebral hemorrhage  
TIA   - Transient Ischemic Attack  
COPD  -  Chronic Obstructive Pulmonary Disease 
PT   - Pulmonary Tuberculosis 
BA   - Bronchial Asthma 
CRF   -  Chronic Renal Failure 
MVP   - Mitral Valve Prolapse 
RHD   - Rheumatic Heart Disease 
 
 
 
 
NO. IPNO. AGE SEX PAST H/O PERSONAL H/O CT FINDINGS 
ADMISSION DAY 
BLOOD-GLUCOSE 
NIHSS 
 
 
 
HBA1C 
 
OUTCOME 
1 16389 47 M DM/ CAHD Alcoholic/Smoker Lt MCA &PCA infarct 160 12 - Moderate 
2 16299 65 M - Smoker/Alcoholic Lt MCA infarct 140 10 6.2 Moderate 
3 25711 41 F HT - Lt MCA infarct 91 6 - Good 
4 14102 72 F TIA/ - RT MCA infarct 151 12 6 Moderate 
5 25791 65 M CAHD Alcholic Hemorrhage In Lt Thalamus region 131 23 6.2 Poor 
6 35104 72 M - Alcholic Infarct Lt MCA Area 81 7 - Good 
7 35809 67 M HT - Infarct in RT MCA Area 91 6 - Good 
8. 35161 42 M - Alcoholic Hemorrhage in Rt ventricle 161 25 6.2 Death 
9. 33124 60 M - Smoke/Alcoholic Infarct in parieto Occipital region 141 14 6.1 Moderate 
10. 35187 76 M HT - Left Frontal Hemorrhage 152 26 6 Death 
11 24186 65 F HT/TIA  Rt MCA infarct 163 16 6.2 Poor 
12 65836 70 M HT/ Alcoholic Hemorrhage in Lt fronto Parietal Area 125 8 - Good 
13 67165 70 M HT/ DM Alcoholic/Smoker Infarct LT MCA Area 165 18 - Poor 
14 60600 60 M HT Alcoholic/smoker Hemorrhage in Rt Frontal Hemorrhage 166 25 9 Poor 
15 30355 50 M  Alcoholic Multiple infarct in Rt cerebral hemisphere 160 22 7 Poor 
16 59550 45 M - Alcoholic Multiple infarct in Rt Cerebral hemisphere 145 17 6.1 Death 
17. 37705 59 M HT Alcoholic/Smoker Hemorrhage in parietal area 91 7 - Good 
18 68466 80 F HT/DM  Lt MCA infarct 222 16 - Poor 
19 38466 62 M HT/ DM Smoker Rt MCA infarct 177 22 - Poor 
20 75836 63 M HT Alcoholic Rt MCA infarct  167 18 8 Poor 
21 66222 66 M HT/ DM Alcoholic/Smoker Hemorrhage in fronto Parietal Area 248 24 - Poor 
22 213234 66 F HT/ DM  Rt MCA Infarct 201 22 - Poor 
23 24442 48 M - Alcoholic Hemorrhage in frontal area 81 7 - Good 
NO. IPNO. AGE SEX PAST H/O PERSONAL H/O CT FINDINGS 
ADMISSION DAY 
BLOOD-GLUCOSE 
NIHSS 
 
 
 
HBA1C 
 
OUTCOME 
24 214232 42 F CAD  Lt MCA Infarct 92 6 - Good 
25. 234543 45 F -  Rt MCA infarct/midlins shift 145 8 6.1 Death 
26 213423 48 M - Alcoholic Rt MCA infarct/midline shift 198 10 8 Death 
27 312021 50 M - - Lt MCA infarct 199 16 6.1 Poor 
28 213423 70 F DM  Hemorrhage in Rt parieto occipital area 214 23 - Death 
29 312293 60 M -  Hemorrhage in Rt frontal area 334 25 7 Poor 
30 49015 73 M HT  Lt MCA infarct 85 7 - Good 
31 25836 60 F DM  RtMCA infarct/midline shift 300 10 - Death 
32 37165 77 M DM  Lt MCAinfarct 232 16 - Poor 
33 58430 56 M CAHD Smoker/ Alcoholic Lt MCA infarct 90 7 - Good 
34 55836 70 F HT/DM  Lt MCA infarct 218 16 - Poor 
35 68430 82 M  Alcoholic Lt MCA infarct /midline Shift  140 9 6 Death 
36 35891 60 F HT/DM  Rt MCA Infarct 189 16 - Poor 
37 58447 69 M HT/DM  Lt MCA Infarct 199 16 - Poor 
38 42490 58 F HT  RtMCA infarct 92 7 - Good 
39 43953 41 M  Smoker/ Alcoholic Rt ICH with intraventricular extension 198 23 6 Death 
40 43903 67 F HT/DM  Parietal hemorrhage 240 10 - Death 
41 42653 60 F HT  Lt MCA infarct 92 7 - Good 
42 41467 50 M   RtMCA infarct 89 7 - Good 
43 42708 70 M   Lt MCA infarct 144 16 6.2 Poor 
44 42705 75 M  Alcoholic Lt MCA infarct 124 10 6.5 Poor 
45 42687 43 M  Smoker/ Alcoholic Lt MCA& PCA infarct 149 10 6.5 Death 
46 43997 65 F   Lt MCA infarct 87 7 - Good 
47 63162 88 F   Lt  massive MCA infarct 144 10 7 Death 
NO. IPNO. AGE SEX PAST H/O PERSONAL H/O CT FINDINGS 
ADMISSION DAY 
BLOOD-GLUCOSE 
NIHSS 
 
 
 
HBA1C 
 
OUTCOME 
48 54361 75 F HT/DM  Lt MCA infarct/midline shift 135 7 - Death 
49 41572 74 M   parietal infarct 92 6 - Good 
50 53521 56 M CAHD  Rt MCA infarct 123 10 6.1 Poor 
51 36431 67 M CAHD  Lt MCA infarct 89 7 - Poor 
52 35413 58 M CAHD  Lt MCA INFARCT 95 7 - Poor 
53 33514 61 M CAHD Smoking Lt MCA infarct/ midline shift 147 9 6 Death 
54 38156 73 M CAHD Smoking/Alcoholic Lt massive MCA infarct 194 14 8 Death 
55 32501 53 M HT  Rt MCA infarct 142 10 6.1 Moderate 
56 32506 48 M HT/DM  Lt MCA infarct 160 10 - Moderate 
57 73721 55 M CAHD/ DM  Rt MCA infarct/ midline shift 180 10 - Death 
58 41575 68 M CAHD/ Alcoholic Lt MCA infarct 140 10 6 Moderate 
59 32568 61 M HT  Rt MCA infarct 150 17 6.5 Poor 
60 35512 62 M HT Alcoholic Rt MCA infarct 88 7 - Good 
61 63125 61 F HT/DM  Lt MCA infarct 178 15 - Poor 
62 64332 60 M HT Alcoholic Lt MCA infarct 152 14 6.5 Poor 
63 46122 62 M CAHD/DM  Lt massive MCA infarct 164 10 - Death 
64 49586 65 M CAHD  Frontal infarct 78 7 - Good 
65 43758 61 M CAHD Alcoholic Cerebellar infarct 90 7 - Good 
66 51523 59 M CAHD/ DM  Rt MCA infarct 112 10 - Moderate 
67 41532 72 M CAHD/ DM Alcoholic Lt MCA infarct 241 14 - Poor 
68 61108 52 M DCM/AF  Parietal  infarct 88 7 - Good 
69 45324 61 F   Rt MCA infarct 173 7 6.1 Good 
70 53254 55 F CAHD  Hemorrhage in capsulo ganglion area 197 15 10.4 Moderate 
71 26858 60 M HT  Rt MCA infarct 121 14 6.1 Poor 
NO. IPNO. AGE SEX PAST H/O PERSONAL H/O CT FINDINGS 
ADMISSION DAY 
BLOOD-GLUCOSE 
NIHSS 
 
 
 
HBA1C 
 
OUTCOME 
72 21615 65 M CAHD Alcoholic Lt MCA infarct 92 7 - Good 
73 35462 53 M CAHD Alcoholic Temporal hemorrhage 92 7 - Good 
74 28017 59 M DM/HT/ CAHD  Parieto temporal hemorrhage 187 10 - Moderate 
75 28481 53 M CAHD Smoking/ Alcoholic Lt MCA infarct 123 17 6 Poor 
76. 28292 59 M CAHD  Parieto temporal hemorrhage 101 10 - Moderate 
78 65332 79 M  Smoking Rt massive MCA infarct/ midline shift 145 9 6 Death 
79 35421 76 M CAHD Smoking/ Alcoholic Rt MCA with PCA, watershed zone infarct 121 25 6 Death 
80 45231 53 M CKD  Lt ICH 98 25 - Death 
81 87768 65 F HT  Rt MCA infarct 88 7 - Good 
82 25480 55 M  Alcoholic Lt MCA infarct/ midline shift 87 17 - Death 
83 25521 45 M  Alcoholic Frontal infarct 72 7 - Good 
84 23539 47 M HT smoking Rt MCA infarct 138 15 6.5 Poor 
85 29195 63 M HT  Lt MCA infarct 92 7 - Moderate 
86 45841 60 M HT Smoking/alcohol Rt MCA infarct 152 15 6.5 Poor 
87 58430 60 M HT Smoking/ Alcoholic Rt MCA with PCA, watershed zone infarct 166 10 6.1 Poor 
88 39105 64 M HT/CKD/ DM  Hemorrhage in Rt parietal lobe 189 15 - Poor 
89 47615 45 M HT Smoking/ Alcohol Rt ICH with dilated ventricle with midline shift 154 25 10.2 Death 
90 39125 60 F   Rt MCA INFARCT 172 15 7 Poor 
91 48625 47 F HT  Rt ICH 210 16 8 Poor 
92 37619 58 F HT  Rt MCA infarct 99 7 - Good 
93 27915 65 F DM/HT  Massive Rt MCA infarct 288 25 - Death 
94 17676 56 F   Lt MCA infarct 72 7 - Moderate 
95 17915 50 F CAHD  Rt ACA infarct 194 10 10 Moderate 
NO. IPNO. AGE SEX PAST H/O PERSONAL H/O CT FINDINGS 
ADMISSION DAY 
BLOOD-GLUCOSE 
NIHSS 
 
 
HBA1C 
 
OUTCOME 
96  40 F HT  ICH with intraventricular extension 178 18 6.1 Poor 
97  66 F DCM/AF  Parieto temporal hemorrhage 152 15 6 Moderate 
98  62 F   Lt MCA infarct 85 7 - Moderate 
99  42 F   Rt MCA infarct 188 15 7 Poor 
100  40 F DM  Lt MCA infarct 208 15 - Moderate 
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